EGFR and head and neck squamous cell carcinoma: Nevertheless, while EGFR is expressed in more than 90% of HNSCC and is a clinically validated therapeutic target in HNSCC [41], the other two family members are less commonly expressed [42] and its targeting has resulted in modest clinical success so far [43].